Отправить статью по E-mail Safe Use of Systemic Interferons for Multiple Sclerosis Treatment
- Авторы: Snegireva I.I.1, Darmostukova M.A.1, Kazakov A.S.1, Lepakhin V.K.1
-
Учреждения:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- Выпуск: Том 52, № 10 (2019)
- Страницы: 863-864
- Раздел: Drugs
- URL: https://journal-vniispk.ru/0091-150X/article/view/245514
- DOI: https://doi.org/10.1007/s11094-019-1916-8
- ID: 245514
Цитировать
Открытый доступ
Доступ предоставлен
Только для подписчиков
Аннотация
The safety of interferons was assessed by analyzing 499 spontaneous reports in the Russian database from 2015 to 2017. The results led to the conclusion that the safety profile of systemic interferon preparations that are widely used in medical practice to treat multiple sclerosis is defined by data in spontaneous reports for the development of adverse reactions to them or the ineffectiveness of using them.
Ключевые слова
Об авторах
I. Snegireva
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Автор, ответственный за переписку.
Email: SnegirevaII@expmed.ru
Россия, 8/2 Petrovskii Blvd, Moscow, 127051
M. Darmostukova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Россия, 8/2 Petrovskii Blvd, Moscow, 127051
A. Kazakov
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Россия, 8/2 Petrovskii Blvd, Moscow, 127051
V. Lepakhin
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Россия, 8/2 Petrovskii Blvd, Moscow, 127051
Дополнительные файлы
